The Wisconsin Alumni Research Foundation (WARF) has partnered with Boston-based Ginkgo Bioworks to discover next-generation GD2 CAR T-cell therapies, the organization announced today.

According to a release, CAR T-cell therapies have shown promise for the treatment of blood cancers. WARF and Ginkgo will work on applying CAR T-cell therapies to solid tumors.

“WARF is delighted to see this important collaboration,” WARF CEO Erik Iverson said in a statement. “We know these alliances between our university researchers and leading biotech industry partners have the potential to result in benefits that positively impact human health.”

Ginkgo will collaborate with the University of Wisconsin researchers Krishanu Saha, Ph.D., and Christian Capitini, M.D. The two have collaborated on the development of a GD2 CAR T-cell therapeutic candidate for the treatment of neuroblastoma, a type of cancer that generally affects young children.